News headlines about Opko Health (NASDAQ:OPK) have been trending positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Opko Health earned a news sentiment score of 0.42 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 88 out of 100, indicating that recent media coverage is very likely to have an effect on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s analysis:
- ETFs with exposure to OPKO Health, Inc. : July 28, 2017 (finance.yahoo.com)
- Phillip Md Et Al Frost Purchases 23,600 Shares of Opko Health, Inc. (NASDAQ:OPK) Stock (americanbankingnews.com)
- Opko: Contrarian Play On Positive Update – Seeking Alpha (seekingalpha.com)
- Short Interest in Opko Health, Inc. (NASDAQ:OPK) Drops By 2.2% (americanbankingnews.com)
- Opko Health, Inc. (NASDAQ:OPK) Stock Rating Reaffirmed by Jefferies Group LLC (americanbankingnews.com)
Several research analysts recently commented on OPK shares. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $19.50 price target on shares of Opko Health in a research note on Friday, June 16th. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Barrington Research increased their price objective on shares of Opko Health to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, July 18th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $8.00 price target on shares of Opko Health in a research report on Monday, June 12th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Opko Health presently has a consensus rating of “Buy” and a consensus target price of $14.72.
Opko Health (NASDAQ OPK) traded down 0.16% during midday trading on Friday, hitting $6.31. 2,956,712 shares of the stock were exchanged. The company’s market capitalization is $3.53 billion. Opko Health has a 1-year low of $5.99 and a 1-year high of $12.15. The company’s 50 day moving average is $6.48 and its 200 day moving average is $7.46.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. The company had revenue of $296.10 million for the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The company’s quarterly revenue was up 1.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.02) earnings per share. Analysts predict that Opko Health will post ($0.20) earnings per share for the current fiscal year.
In related news, CEO Phillip Md Et Al Frost acquired 4,700 shares of the company’s stock in a transaction dated Monday, May 1st. The stock was purchased at an average price of $7.68 per share, with a total value of $36,096.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $23,569,543.68. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Vice Chairman Jane Ph D. Hsiao purchased 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 10th. The stock was acquired at an average cost of $6.97 per share, with a total value of $278,800.00. Following the purchase, the insider now directly owns 24,723,133 shares of the company’s stock, valued at $172,320,237.01. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 2,801,800 shares of company stock worth $18,720,931. 40.19% of the stock is owned by company insiders.
WARNING: “Favorable Press Coverage Very Likely to Affect Opko Health (OPK) Stock Price” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/07/29/favorable-media-coverage-very-likely-to-affect-opko-health-opk-share-price-updated-updated-updated.html.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.